Personalized drug discovery: HCA approach optimized for rare diseases at tel aviv university

Combinatorial Chemistry and High Throughput Screening

Volumn 17, Issue 3, 2014, Pages 253-255

  Solmesky, Leonardo J ^a   Weil, Miguel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Drug repurposing; High content screening; Nanomaterials characterization; Personalized drug discovery; Personalized medicine; Rare diseases

Indexed keywords

NEW DRUG; MOLECULAR LIBRARY;

ARTICLE; CELL SCREENING; DRUG DEVELOPMENT; DRUG REPOSITIONING; FOOD AND DRUG ADMINISTRATION; HUMAN; ISRAEL; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOPHORE; PRIORITY JOURNAL; RARE DISEASE; DRUG SCREENING; DYSAUTONOMIA, FAMILIAL; INTESTINAL PSEUDO-OBSTRUCTION; MITOCHONDRIAL ENCEPHALOMYOPATHIES; MOLECULAR LIBRARY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PHARMACOLOGY; PROCEDURES; RARE DISEASES; UNIVERSITY;

DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; DYSAUTONOMIA, FAMILIAL; HUMANS; INDIVIDUALIZED MEDICINE; INTESTINAL PSEUDO-OBSTRUCTION; ISRAEL; MITOCHONDRIAL ENCEPHALOMYOPATHIES; RARE DISEASES; SMALL MOLECULE LIBRARIES; UNIVERSITIES;

EID: 84897994577     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207317666140109123249     Document Type: Article

References (17)

1. Sharma, A.; Jacob, A.; Tandon, M.; Kumar, D. Orphan drug: Development trends and strategies. J. Pharm. Bioallied Sci., 2010, 2 (4), 290-299.
2. Girirajan, S.; Eichler, E.E. Phenotypic variability and genetic susceptibility to genomic disorders. Hum. Mol. Genet, 2010, 19 (R2), R176-187.
3. Solmesky, L.J.; Abekasis, M.; Bulvik, S.; Weil, M. Bone morphogenetic protein signaling is involved in human mesenchymal stem cell survival in serum-free medium. Stem Cells Dev., 2009, 18 (9), 1283-1292.
4. Solmesky, L.; Lefler, S.; Jacob-Hirsch, J.; Bulvik, S.; Rechavi, G.; Weil, M. Serum free cultured bone marrow mesenchymal stem cells as a platform to characterize the effects of specific molecules. PLoS One, 2010, 5 (9), e12689.
5. Solmesky, L.J. Characterization of Human Mesenchymal Stem Cells from Bone Marrow, 1st ed.; Lambert Academic Publishing: Saarbruken, Germany, 2012.
6. Slaugenhaupt, S.A.; Blumenfeld, A.; Gill, S.P.; Leyne, M.; Mull, J.; Cuajungco, M.P.; Liebert, C.B.; Chadwick, B.; Idelson, M.; Reznik, L.; Robbins, C.; Makalowska, I.; Brownstein, M.; Krappmann, D.; Scheidereit, C.; Maayan, C.; Axelrod, F.B.; Gusella, J.F. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am. J. Hum. Genet., 2001, 68 (3), 598-605.
7. Rothstein, J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 2009, 65 (Suppl 1), S3-9.
8. Piaceri, I.; Del Mastio, M.; Tedde, A.; Bagnoli, S.; Latorraca, S.; Massaro, F.; Paganini, M.; Corrado, A.; Sorbi, S.; Nacmias, B. Clinical heterogeneity in Italian patients with amyotrophic lateral sclerosis. Clin. Genet., 2012, 82 (1), 83-87.
9. Nachmany, H.; Wald, S.; Abekasis, M.; Bulvik, S.; Weil, M. Two potential biomarkers identified in mesenchymal stem cells and leukocytes of patients with sporadic amyotrophic lateral sclerosis. Dis Markers, 2012, 32 (4), 211-220.
10. Lilo, E.; Wald-Altman, S.; Solmesky, L.J.; Ben Yaakov, K.; Gershoni-Emek, N.; Bulvik, S.; Kassis, I.; Karussis, D.; Perlson, E.; Weil, M. Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1G93A mouse model. Hum Mol Genet, 2013, 2(23), 4720-4725.
11. Palomino, J.C.; Martin, A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J. Antimicrob. Chemother., 2013, 68 (2), 275-283.
12. Sardana, D.; Zhu, C.; Zhang, M.; Gudivada, R.C.; Yang, L.; Jegga, A.G. Drug repositioning for orphan diseases. Brief Bioinform., 2011, 12 (4), 346-356.
13. Tobinick, E.L. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect., 2009, 22 (2), 119-125.
14. Roe, C.R.; Bottiglieri, T.; Wallace, M.; Arning, E.; Martin, A. Adult Polyglucosan Body Disease (APBD): Anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways. Mol. Genet. Metab., 2010, 101 (2-3), 246-252.
15. Kakhlon, O.; Glickstein, H.; Feinstein, N.; Akman, H.; DiMauro, S.; Minassian, B.; Michaeli, A.; Rayan, A.; Grossman, T.; Solmesky, L.; Weil, M.; Kozakov, D.; Lossos, A. Searching for Efficient Therapeutic Avenues To Treat Adult Polyglucosan Body Disease (APBD) and Lafora Disease (LD) Using a High-Throughput Screening Platform. Neurology, 2013, 80 (Meeting abstracts I), P03.053.
16. Solmesky, L.J.; Shuman, M.; Goldsmith, M.; Weil, M.; Peer, D. Assessing cellular toxicities in fibroblasts upon exposure to lipidbased nanoparticles: A high content analysis approach. Nanotechnology, 2011, 22 (49), 494016.
17. Dvash, R.; Khatchatouriants, A.; Solmesky, L.J.; Wibroe, P.P.; Weil, M.; Moghimi, S.M.; Peer, D. Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. J. Control Release, 2013, 170 (2), 295-305.